Cellectis bioresearch launches cGPS® CHO-S CEMAX® – an efficient protein production kit
Paris — Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), today launched cGPS® CHO-S CEMAX®, a kit which enables targeted integration into suspension cell cultures. By reducing the amount of time required to obtain clones and by
improving production stability, this kit represents an advancement in the production of recombinant proteins and monoclonal antibodies. It will make producing antibodies for research and diagnostic easier.
Cell volume and concentration are much greater in suspension cell cultures than in adherent cell cultures. Because it enables targeted integration into CHO cells cultured in suspension in a specific site allowing strong protein expression, the cGPS CHO-S CEMAX kit opens up a whole new realm of applications.
“The cGPS CHO-S CEMAX kit was developed using Celonic’s CEMAX® technology that we received a license to commercialize just over 5 months ago,” said Luc Selig, VP Sales & Marketing at Cellectis bioresearch. “By optimizing CEMAX®, which is based on our technologies, for use with our kits we can now provide laboratories with a pioneering product.”
“Our teams have shown that they are able to expand our product portfolio in a short space of time through in-licensing,” added Marc Le Bozec, CEO at Cellectis bioresearch. “This new product offers performance capabilities that have never been available until now.”
The targeted integration kits – cGPS® (cellular Genome Positioning System) and cGPS® Custom – can be purchased via the company’s website at www.cellectis-bioresearch.com.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in
June 2008. It provides life science researchers with genome customization kits for rapid,
efficient gene integration at a precise genomic position in a given cell type.
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €50 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS).
For more information on Cellectis, visit our website: www.cellectis.com
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forwardlooking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers (“AMF”) granted its visa n° 07-023 on January 22, 2007, could
cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
